Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Cash & Equivalents (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Cash & Equivalents for 14 consecutive years, with $3.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents rose 161.0% year-over-year to $3.9 million, compared with a TTM value of $3.9 million through Sep 2025, up 161.0%, and an annual FY2024 reading of $547890.0, down 38.05% over the prior year.
  • Cash & Equivalents was $3.9 million for Q3 2025 at BioRestorative Therapies, down from $5.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $21.0 million in Q4 2021 and bottomed at $547890.0 in Q4 2024.
  • Average Cash & Equivalents over 5 years is $6.9 million, with a median of $3.2 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents skyrocketed 52220.27% in 2021, then plummeted 91.95% in 2025.
  • Year by year, Cash & Equivalents stood at $21.0 million in 2021, then crashed by 91.85% to $1.7 million in 2022, then crashed by 48.4% to $884377.0 in 2023, then plummeted by 38.05% to $547890.0 in 2024, then surged by 609.52% to $3.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for BRTX at $3.9 million in Q3 2025, $5.8 million in Q2 2025, and $1.2 million in Q1 2025.